Immunic (IMUX) Capital Expenditures (2013 - 2026)

Immunic has disclosed Capital Expenditures across 14 years of filings, most recently posting $2000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $2000.0, down 95.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $116000.0 (down 58.57% YoY), and the FY2025 annual result was $161000.0, down 39.02% from the prior year.
• Capital Expenditures came in at $2000.0 for Q1 2026 at Immunic, down from $11000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $180000.0 in Q2 2024 to a low of -$1000.0 in Q4 2022.
• The 5-year median for Capital Expenditures is $36000.0 (2025), against an average of $51352.9.
• Across the five-year window, Capital Expenditures sank 105.26% in 2022 and surged 16600.0% in 2023, its largest moves.
• Immunic's Capital Expenditures stood at -$1000.0 in 2022, then soared by 16600.0% to $165000.0 in 2023, then plunged by 98.18% to $3000.0 in 2024, then soared by 266.67% to $11000.0 in 2025, then slumped by 81.82% to $2000.0 in 2026.
• The last three Capital Expenditures figures came in at $2000.0 (Q1 2026), $11000.0 (Q4 2025), and $67000.0 (Q3 2025), per Business Quant data.